je.st
news
Tag: biologic
BIO Urges Governor to Sign interchangeable biologic medicine bill.
2015-04-07 14:31:09| Industrial Newsroom - All News for Today
BIO is calling upon Governor Deal to sign legislation to create pathway for substitution of interchangeable biologic medicines. Policies outlined in Bill 51, which passed Georgia Senate with 43-3 vote following unanimous vote in the House, align with BIO's principles on biologic substitution. BIO President and CEO Jim Greenwood called this legislation, "a significant step forward," citing transparency and communication between patients and their treatment teams.
NGM And Merck Announce Broad Strategic Collaboration To Discover, Develop And Commercialize Novel Biologic Therapeutics
2015-03-04 04:25:06| drugdiscoveryonline News Articles
NGM Biopharmaceuticals, Inc., a privately-held biotechnology company and Merck, known as MSD outside the United States and Canada, recently announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas
Tags: develop
broad
discover
collaboration
NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics
2015-02-23 13:00:00| Merck.com - Corporate News
Dateline City: SOUTH SAN FRANCISCO, Calif. & KENILWORTH, N.J. Partnership Combines NGMs Unique Biology-focused Research Platform with Mercks Late-stage Clinical and Commercialization Strengths to Discover Medicines for Serious Diseases SOUTH SAN FRANCISCO, Calif. & KENILWORTH, N.J.--(BUSINESS WIRE)-- NGM Biopharmaceuticals, Inc., a privately-held biotechnology company and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas. This agreement will become effective upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Language: English Contact: MerckMedia Relations:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestor Relations:Justin Holko, 908-740-1879orNGM BiopharmaceuticalsMedia Relations:Tony Plohoros, 908-940-01356 Degreestplohoros@6degreespr.comorInvestor Relations:Beth DelGiacco, 212-362-1200Stern Investor Relationsbeth@sternir.com Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: develop
broad
discover
collaboration
Cook Pharmica, LLC And Selexis SA Establish Customized Biologic Drug Development And Manufacturing Services Platform
2014-07-02 10:43:44| drugdiscoveryonline Home Page
Cook Pharmica, LLC, a leading biopharmaceutical contract development and manufacturing organization (CDMO), and Selexis SA, a serial innovation company focused on biologic drug discovery and mammalian cell line development, have built a platform program to offer biopharmaceutical clients an integrated development and manufacturing solution for biologic drugs
Tags: services
development
llc
drug
Massachusetts Governor Patrick Signs Bill Granting Patient Access to Interchangeable Biologic ...
2014-06-25 06:00:00| Industrial Newsroom - All News for Today
BIO and the Massachusetts Biotechnology Council commend Massachusetts Governor Deval Patrick for signing legislation designed to create pathway for substitution of interchangeable biologic medicines. House Bill 3734 seeks to properly preserve patient access to accurate prescription information, maintains incentives for innovation, and promotes competitive market for biologic therapies. BIO will continue to advocate for full transparency in the substitution process. This story is related to the following:Trade Associations
Tags: access
bill
patient
signs